ASHM Report Back
Clinical posts from members and guests of the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) from various international medical and scientific conferences on HIV, AIDS, viral hepatitis, and sexual health.
The once daily dosed integrase inhibitor DOLUTEGRAVIR was the subject of a handful of presentations at the conference. Week 96 results from the SPRING-1 study were reported. This was a phase 2 study of 205 people comparing different doses of Dolutegravir (10, 24 and 50mg) with efavirenz, both in combination with a TDF/FTC or ABC/3TC backbone. At week 96 the proportion with a HIV viral load less than 50 copies per ml was 88% in the 50mg dolutegravr arm and 72% in the efavrenz arm (a non signficant difference). The treatment appeared well tolerated, although there was a mild elevation in serum creatinine, thought to be due to effects on renal secretion of creatinine and not real impairment of GFR. Phase 3 studies of this agent, which could provide a once daily integrase inhibitor regimen, are underway.